Clinical Trials Logo

Filter by:
NCT ID: NCT05906836 Completed - Healthy Clinical Trials

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Start date: July 27, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

NCT ID: NCT05906784 Completed - Chronic Pain Clinical Trials

Group-based Integrative Pain Management (IPMP+ Pilot)

Start date: April 28, 2023
Phase: N/A
Study type: Interventional

Socioeconomically disadvantaged populations have a high prevalence of chronic pain, exacerbated by social isolation, intersectional stigma, and disparities in pain assessment and treatment options. Effective interventions using a multilevel, biopsychosocial approach are needed to decrease the unequal burden of pain. The proposed pilot study will test group-based integrative models of pain management in primary care safety net clinics to improve pain care for racially and ethnically diverse low-income patients.

NCT ID: NCT05906667 Completed - Cognitive Change Clinical Trials

Sharing History Through Active Reminiscence and Photo-imagery - With MCI

SHARP-MCI
Start date: May 24, 2017
Phase: Early Phase 1
Study type: Interventional

The SHARP-MCI study tests impact of walking and social reminiscence on cognitive function, blood pressure, and weight among healthy Black Americans and those experiencing mild cognitive impairment (MCI).

NCT ID: NCT05905991 Completed - Burnout Clinical Trials

Enhanced Stress Resilience Training for Critical Care Nurses

Start date: April 25, 2023
Phase: N/A
Study type: Interventional

Job stress and burnout are significant problems affecting physical health, emotional well-being, job performance, and retention of nurses. Enhanced Stress Resilience Training (ESRT) is a theory-driven, evidence-based intervention to increase stress resilience and decrease burnout among clinicians. This study is a randomized waitlist-controlled trial to examine the efficacy, feasibility, and long-term sustainability of the 5-week ESRT intervention to improve psychosocial and occupational well-being of critical care nurses.

NCT ID: NCT05905679 Completed - Clinical trials for Mental Health Wellness

Effects of a Probiotic on Aspects of Mental Wellness

Start date: July 20, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the effect of a probiotic strain on mental wellbeing in moderately stressed, healthy, adults in the general population. The main question it aims to answer is • what is the impact of probiotic consumption on overall mental wellbeing? Participants will consume one probiotic or placebo capsule per day, answer a set of questionnaire (at 3 time points) and wear a wearable device for the total duration of the study.

NCT ID: NCT05905497 Completed - Clinical trials for Healthy Volunteer Study

The Study of Bemnifosbuvir in Healthy Japanese Subjects

Start date: April 26, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects

NCT ID: NCT05904210 Completed - Hemophilia Clinical Trials

Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Start date: November 7, 2023
Phase:
Study type: Observational

Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] in the USA. The current study will provide a unique opportunity to describe the profile of the early patients selected for treatment with SEVENFACT® and to assess the real-world utilization (effectiveness, safety, tolerability, and modalities of treatment) of SEVENFACT®.

NCT ID: NCT05903326 Completed - Effect of Drug Clinical Trials

Dexmedetomidine as a Sole Premedication for BMT Placement

BMT
Start date: February 11, 2022
Phase:
Study type: Observational

There is very little evidence or research documenting any single method of sedation/analgesia for myringotomy tube (BMT) placement as being more effective than others. This was a retrospective chart review conducted to determine if there were significant differences in efficacy of administered pre-operative Midazolam and Intraoperative IM Ketorolac (traditional) vs. pre-operative Dexmedetomidine alone for pain and emergence delirium management of children undergoing placement of BMTs. The current protocol was changed under the direction of anesthesia and team members who wanted to see what the outcomes of the new management plan were. The plan was a prospective chart review and for this project, 276 patient charts were reviewed, 154 patients received traditional anesthesia treatment and 122 received Precedex. Data analysis indicated that the patients who had received Dexmedetomidine had significantly higher FLACC scores (meaning better pain control) than those who received the traditional therapy. There was no difference in emergence delirium between the two groups.

NCT ID: NCT05901883 Completed - Healthy Clinical Trials

First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects

Start date: June 20, 2023
Phase: Phase 1
Study type: Interventional

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CEL383 in healthy volunteers.

NCT ID: NCT05901311 Completed - Healthy Clinical Trials

A Study of [14C]-LY3537982 in Healthy Participants

Start date: June 5, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively.